NCT06334029 Observational Study of the Structural-functional Connectome in Patients With Epilepsy
| NCT ID | NCT06334029 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Eugenio Medea |
| Condition | Epilepsy |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2023-06-22 |
| Primary Completion | 2026-11-22 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2023-06-22 with a primary completion date of 2026-11-22.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Over the past decade, the concept of the brain as a complex network has extremely influenced the way regarding how the latter is studied (Bartolomei et al., 2017). The structure of both structural and functional networks within the brain has been related to optimal brain functioning (Duma et al., 2022). This evolution of methods and approaches of investigation has directly impacted the study of epilepsy. An early conception of focal epilepsy was that it was related to the activity of the epileptogenic zone, which was identified as the generative element of seizures. However, what was previously considered focal was found to be network alterations at various levels, thus moving from the epileptogenic zone to the concept of the epileptogenic network. Alterations in both the structural and functional network, compared with a healthy control population, have been identified in various forms of epilepsy from focal to idiopathic generalized epilepsy (Lariviere et al., 2022, Zhang et al., 2009). Often the identification and removal of the epileptogenic network, turns out to be the elective therapy in drug-resistant focal epilepsies. The process of diagnosing and defining the epileptogenic network is still debated today. One of the most widely used methods is the implantation of intracranial electrodes for electroencephalographic recording of seizures (Bartolomei et al., 2017). This methodology carries with it several, albeit controlled, risks to the patient. New noninvasive approaches are being developed seeking to integrate information from structural neuroimaging and cortical electrical activity measured by high-density electroencephalography with external electrodes (Duma et al., 2021). These new approaches also include simulative approaches that exploit individualized information such as cortex geometry and patient-specific white matter connections (Courtiol et al. 2020). Thus, starting from a simple structural and diffusion MRI, which is done in routine clinical examinations, multiple localizing hypotheses of the epileptogenic network can be tested using simulative models and then compared with the real EEG signal as validation. Of great relevance is also to understand how the structural-functional connectome relates to cognitive function in patients with epilepsy, who have a high probability of presenting impaired functioning in one or more cognitive domains.
Eligibility Criteria
Inclusion Criteria: * a diagnosis of focal or generalized epilepsy confirmed by specialist evaluation; * at least one MRI scan of the brain that includes T1w * at least one recording with resting state EEG * age between 6 and 65 years at the time of the evaluation of the present study; * ability to take part in a neuropsychological assessment. Exclusion Criteria: * vascular causes or non-low grade tumors as causes of epilepsy * age different from the range 6-65 years * neuroradiologic examination not complete * absence of resting state recording * inability to take part in a neuropsychological evaluation.
Contact & Investigator
Gian Marco Duma, PhD
PRINCIPAL INVESTIGATOR
IRCCS E. Medea
Frequently Asked Questions
Who can join the NCT06334029 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 65 Years, studying Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06334029 currently recruiting?
Yes, NCT06334029 is actively recruiting participants. Contact the research team at gianmarco.duma@lanostrafamiglia.it for enrollment information.
Where is the NCT06334029 trial being conducted?
This trial is being conducted at Conegliano, Italy.
Who is sponsoring the NCT06334029 clinical trial?
NCT06334029 is sponsored by IRCCS Eugenio Medea. The principal investigator is Gian Marco Duma, PhD at IRCCS E. Medea. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.